AbbVie Inc.

ticker: ABBV step: 01 generated: 2026-05-11 source: quick-research

AbbVie Inc. (ABBV) — Business Overview

Business Description

AbbVie is a global research-based biopharmaceutical company spun off from Abbott Laboratories in 2013. Its business is anchored by immunology (Skyrizi + Rinvoq + Humira), with sizable franchises in neuroscience, oncology, aesthetics (Allergan's Botox + Juvederm), and eye care. After successfully navigating the largest patent cliff in pharma history (Humira, peak $21.2B sales in 2022), AbbVie's combined Skyrizi + Rinvoq sales exceeded $25B in 2025 and are tracking to >$31B by 2027 — already surpassing peak Humira.

Revenue Model

• Immunology (~45% of revenue): Skyrizi (IL-23), Rinvoq (JAK), residual Humira (TNF) — fast-growing replacements offsetting Humira biosimilar erosion
• Oncology (~10%): Imbruvica (BTK, partnered with J&J), Venclexta, Epkinly, Elahere
• Neuroscience (~14%): Vraylar, Botox Therapeutic, Ubrelvy, Qulipta — growing 17%+ annually
• Aesthetics (~9%): Botox Cosmetic, Juvederm, CoolSculpting (acquired via Allergan 2020)
• Eye Care (~6%): Restasis, Xen, Vuity (presbyopia)
• Other (~16%): Mavyret (HCV), Creon, Hytrin

Products & Services

• Skyrizi (risankizumab): IL-23 inhibitor for psoriasis, psoriatic arthritis, Crohn's, ulcerative colitis — $17.6B in 2025 ($21.5B 2026E)
• Rinvoq (upadacitinib): JAK1 inhibitor for RA, psoriatic arthritis, atopic dermatitis, IBD, vitiligo (filed) — $8.3B in 2025 ($10.1B 2026E)
• Humira (adalimumab): Legacy TNF inhibitor, now ~$2.9B/year and shrinking ~40% annually post-LOE
• Botox / Juvederm: Aesthetics franchise from $63B Allergan acquisition (2020)
• Vraylar: Atypical antipsychotic for bipolar, depression
• Vylept: New Parkinson's drug (FDA approved 2026)
• Pipeline: Tirvapadone (Parkinson's, Phase 3), Entantamig (multiple myeloma, Phase 3), Crohn's combo platform

Customer Base & Go-to-Market

• Patients: Millions globally, often with chronic disease (autoimmune, oncology)
• Prescribers: Specialist physicians (rheumatology, dermatology, gastroenterology, neurology, oncology)
• Payers: US PBMs/insurers, ex-US single-payer systems negotiate aggressively
• Aesthetics channel: Direct to dermatologists and plastic surgeons; consumer awareness via DTC marketing
• Geographic mix: ~75% US revenue, ~25% International

Competitive Position

AbbVie has the most successful biopharma post-LOE transition on record — Skyrizi and Rinvoq combined have already surpassed peak Humira. Moats include (1) strong specialty sales force relationships in immunology, (2) scientifically differentiated mechanisms (IL-23 + JAK selective JAK1), (3) Allergan aesthetics distribution franchise, and (4) capital allocation discipline using free cash flow for tuck-in M&A (ImmunoGen, Cerevel) to refresh pipeline. Competes with J&J (Stelara, Tremfya), Eli Lilly (Olumiant, Omvoh), Bristol-Myers (Sotyktu), Pfizer (Xeljanz), Roche (Vabysmo) across therapy areas.

Key Facts

• Founded: 2013 (spin off from Abbott Labs)
• Headquarters: North Chicago, IL
• Employees: ~55,000
• Exchange: NYSE
• Sector / Industry: Health Care / Pharmaceuticals
• Market Cap: ~$365B (May 2026)
• CEO: Rob Michael (succeeded Richard Gonzalez 2024)
• Dividend: ~$6.59 annual; 52+ consecutive years (counting Abbott history) — Dividend King via predecessor lineage

ticker: ABBV step: 12 generated: 2026-05-11 source: quick-research

AbbVie Inc. (ABBV) — Investment Catalysts & Risks

Bull Case Drivers

1. Skyrizi + Rinvoq exceeding peak Humira already — Combined 2025 sales of $25.9B already exceed Humira's $21.2B 2022 peak. Q1 2026: Skyrizi +30.9% to $4.48B, Rinvoq +20%. Mgmt raised 2027 combined target to >$31B (from prior $27B). The IL-23 + JAK-selective combo is winning indication after indication — psoriasis, PsA, Crohn's, UC, atopic dermatitis, vitiligo (filed). This proves the post-Humira transition is more successful than original guidance suggested.

2. 2026 inflection: 9.5% revenue growth, EPS $14.37-14.57 — Management's 2026 guidance demonstrates the company has decisively cleared the Humira biosimilar headwind. With Humira now <$3B/year and shrinking ~40% annually (stable run-rate $1-2B by 2027), every dollar of Skyrizi/Rinvoq growth drops to revenue. Operating leverage from immunology growth + cost discipline pushes Adj OM toward 48-49%.

3. Neuroscience as the next growth pillar — Vraylar (+17%) is a $3.5B drug growing as a leading bipolar/depression treatment. Cerevel acquisition added tirvapadone (Parkinson's, Phase 3) and emraclidine. Vylept (FDA approved 2026) adds another Parkinson's asset. Phase 3 success for tirvapadone could add $2B+ annually.

4. 3.2% dividend yield + 52-year track record — AbbVie inherits the Abbott dividend lineage; combined the family has paid an increasing dividend for 52+ consecutive years. The dividend is well covered with FCF ($21B FCF vs $11.5B dividend). Combined with 14x forward P/E, this is a "GARP + yield" stock in a sector facing political headline risk.

Bear Case Risks

1. Humira erosion accelerating + Imbruvica IRA pricing — Humira -39% YoY in Q1 2026 to $688M with continued biosimilar share losses. Imbruvica (J&J-partnered) faces IRA Medicare price negotiations — sales guided to $2.2B in 2026 (-23%). Combined Humira + Imbruvica headwind is ~$1.5B/year drag on growth.

2. Skyrizi/Rinvoq LOE eventually — Skyrizi US LOE ~2032; Rinvoq US LOE ~2034. While distant, biopharma multiples typically compress 4-5 years pre-LOE. The current bull thesis assumes pipeline (Cerevel/ImmunoGen acquisitions, Crohn's combo, AbbVie internal R&D) successfully covers a second cliff. Failure to land another 3-4 blockbusters by 2028 risks repeating the patent cliff cycle.

3. Aesthetics weakness — Botox Cosmetic and Juvederm growth slowing (+4% in 2024) as discretionary consumer spending softens and GLP-1 weight-loss users reportedly need less facial filler. Q4 2025 commentary highlighted aesthetics softness; this previously high-margin segment provides less offset to other categories.

4. Debt + M&A discipline test — $67B total debt post-Allergan/Cerevel/ImmunoGen is large. Management has prioritized deleveraging but the pace depends on FCF stability. If immunology pricing pressure increases (IRA Part D negotiations, EU price referrals), the deleveraging pace slows, constraining further pipeline-refresh M&A.

Upcoming Events

• Q2 2026 earnings (late July) — Skyrizi/Rinvoq trajectory; Humira run-rate visibility
• Q3 2026 earnings (October) — Vitiligo Rinvoq approval / launch trajectory
• Tirvapadone Phase 3 readout — Late 2026 / Early 2027 — Parkinson's data could de-risk pipeline
• Crohn's combo data — Skyrizi + Rinvoq combo for severe IBD — pivotal data through 2026-27
• Entantamig (multiple myeloma) Phase 3 — Potential 2026-27 readout

Analyst Sentiment

Sell-side consensus is Buy / Strong Buy with average price targets in the $230-250 range vs. recent ~$203 trading levels (~13-23% upside). Bulls cite the proven post-Humira transition, 9.5% guided revenue growth, 14x P/E, and 3.2% dividend. Bears focus on the eventual Skyrizi/Rinvoq LOE, Imbruvica IRA decline, and aesthetics weakness. Net consensus is positive but multiple compression at LOE remains a long-term overhang.

Research Date

Generated: 2026-05-11